Bronchial Spasm Market Report 2026

The bronchial spasm market size has grown strongly in recent years. It will grow from $3.82 billion in 2025 to $4.08 billion in 2026 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to increasing prevalence of asthma and copd, widespread use of bronchodilator medications, expansion of inhalation drug delivery systems, growing awareness of respiratory health, availability of generic inhaler formulations.

The bronchial spasm market size is expected to see strong growth in the next few years. It will grow to $5.35 billion in 2030 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to increasing demand for personalized respiratory therapies, rising integration of digital inhaler monitoring, expansion of homecare respiratory management, growing focus on preventive pulmonary care, increasing development of novel bronchodilator formulations. Major trends in the forecast period include increasing adoption of combination inhaler therapies, rising demand for fast-acting rescue medications, growing use of smart inhaler devices, expansion of home-based respiratory care solutions, enhanced focus on personalized respiratory treatment.

The rising prevalence of respiratory diseases is expected to boost the growth of the bronchial spasm market in the future. Respiratory diseases are conditions affecting the respiratory system, leading to breathing difficulties and reduced oxygen intake. The prevalence of respiratory diseases is increasing due to higher air pollution levels that expose populations to harmful particulates and pollutants over long periods. Bronchial spasm contributes to respiratory disease diagnosis by highlighting airway muscle constriction that restricts airflow and serves as a key indicator for conditions such as asthma and chronic obstructive pulmonary disease. For example, in December 2023, according to the National Center for Biotechnology Information, a US-based government agency, COPD cases are projected to increase by 112 million, reaching 592 million globally by 2050, representing 9.5% of the eligible population. Therefore, the rising prevalence of respiratory diseases is supporting the growth of the bronchial spasm market.

Leading companies operating in the bronchial spasm market are emphasizing the development of innovative solutions, such as rescue combination inhalers, to deliver rapid symptom relief while simultaneously managing underlying airway inflammation, improving patient outcomes, and supporting better adherence. A rescue combination inhaler delivers both a fast-acting bronchodilator for immediate relief and an anti-inflammatory medication to control airway inflammation. For example, in January 2024, AstraZeneca plc, a US-based biopharmaceutical company, received FDA approval for AIRSUPRA (albuterol and budesonide), an anti-inflammatory rescue inhaler for adults aged 18 and above with asthma. The therapy offers quick relief from bronchial spasms while lowering the risk of acute exacerbations and aligns with updated asthma treatment guidelines promoting combined symptom and inflammation management. Clinical trial results showed that patients using this therapy achieved faster bronchodilation, experienced fewer severe respiratory events, and demonstrated improved overall disease control, supporting better outcomes for individuals with chronic airway disorders.

In October 2025, Merck & Co. Inc., a US-based pharmaceutical company, acquired Verona Pharma plc for an undisclosed amount. Through this acquisition, Merck expanded its respiratory care portfolio by gaining access to Verona’s inhaled COPD treatment, Ohtuvayre, which helps manage airway narrowing and bronchial spasms in adult patients. Verona Pharma plc is a UK-based company focused on developing therapies for respiratory conditions such as chronic obstructive pulmonary disease and asthma-related disorders.

Major companies operating in the bronchial spasm market are Merck & Co. Inc., Pfizer Inc., Sanofi S.A., Novartis AG, AstraZeneca plc, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Viatris Inc., Menarini Group, Sandoz AG, Chiesi Farmaceutici S.p.A., Cipla Ltd., Lupin Pharmaceuticals Inc., Glenmark Pharmaceuticals Ltd., Amphastar Pharmaceuticals Inc., Nephron Pharmaceuticals Corporation, Beximco Pharmaceuticals Ltd., Circassia Group, Sunovion Pharmaceuticals Inc., PARI Medical Holding GmbH.

Tariffs are impacting the bronchial spasm market by increasing costs of imported active pharmaceutical ingredients, inhaler devices, propellants, packaging materials, and precision manufacturing equipment. Pharmaceutical manufacturers in North America and Europe are most affected due to globalized drug supply chains, while Asia-Pacific faces cost pressures in generic drug production and exports. These tariffs are contributing to higher treatment costs and supply chain complexity. However, they are also encouraging domestic api production, localized inhaler manufacturing, and increased investment in regional pharmaceutical supply resilience.

The bronchial spasm market research report is one of a series of new reports that provides bronchial spasm market statistics, including bronchial spasm industry global market size, regional shares, competitors with a bronchial spasm market share, detailed bronchial spasm market segments, market trends and opportunities, and any further data you may need to thrive in the bronchial spasm industry. This bronchial spasm market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Bronchial spasm is the abrupt and involuntary tightening of the smooth muscles surrounding the bronchial airways, causing airway narrowing, increased resistance to airflow, and reduced air movement into the lungs. This condition leads to symptoms including wheezing, chest constriction, ongoing coughing, and breathlessness, and is commonly linked to asthma, allergic responses, respiratory infections, and chronic obstructive pulmonary disease.

The primary drug types used for bronchial spasm include bronchodilators, anti-inflammatory agents, and combination therapies. Bronchodilators are medications that relax bronchial smooth muscles to enhance airflow and reduce bronchospasm. These treatments are delivered through inhalation, oral, or injectable administration routes. They are employed alongside diagnostic types such as imaging tests, spirometry tests, and other diagnostic methods. The distribution channels comprise hospital pharmacies, retail pharmacies, and online pharmacies, and the end users include hospitals, specialty clinics, and homecare environments.

The bronchial spasm market consists of sales of bronchodilator inhalers, nebulizer solutions, oral bronchodilator tablets, corticosteroid inhalers, combination inhalers, anticholinergic inhalers, rescue inhalers, dry powder inhalers, metered dose inhalers, and inhalation accessories. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.